Published in final edited form as:

J Surg Res. 2015 June 1; 196(1): 172–179. doi:10.1016/j.jss.2015.02.011.

Abnormal myofiber morphology and limb dysfunction in claudication

Panagiotis Koutakis, MS^a, Sara A. Myers, PhD^b, Kim Cluff, PhD^c, Duy M. Ha, BS^a, Gleb Haynatzki, PhD^d, Rodney D. McComb, MD^e, Koji Uchida, PhD^f, Dimitrios Miserlis, MD, BS^a, Evlampia Papoutsis, BS^a, Jason M. Johanning, MD^{a,g}, George P. Casale, PhD^{a,*}, and Iraklis I. Pipinos, MD, PhD^{a,g,**}

George P. Casale: gpcasale@unmc.edu; Iraklis I. Pipinos: ipipinos@unmc.edu

^aDepartment of Surgery, University of Nebraska Medical Center, Omaha, Nebraska

^bNebraska Biomechanics Core Facility, University of Nebraska Omaha, Omaha, Nebraska

^cDepartment of Industrial & Manufacturing Engineering, Wichita State University, Wichita, Nebraska

^dDepartment of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska

^eDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska

^fLaboratory of Food and Biodynamics, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya, Japan

^gDepartment of Surgery and VA Research Service, VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska

Abstract

Background—Peripheral artery disease (PAD), which affects an estimated 27 million people in Europe and North America, is caused by atherosclerotic plaques that limit blood flow to the legs. Chronic, repeated ischemia in the lower leg muscles of PAD patients is associated with loss of normal myofiber morphology and myofiber degradation. In this study, we tested the hypothesis that myofiber morphometrics of PAD calf muscle are significantly different from normal calf muscle and correlate with reduced calf muscle strength and walking performance.

*Corresponding author. Department of Surgery, University of Nebraska Medical Center 987690, Omaha, NE 68198 7690. Tel.: +1 402 559 4623; fax: +1 402 559 6749. **Corresponding author. Department of Surgery, University of Nebraska Medical Center 983280, Omaha, NE 68198 7690. Tel.: +1 402 559 6774; fax: +1 402 559 6749.
Authorship note: G.P.C. and I.I.P. are co-senior authors.

Authors' contributions: P.K., G.P.C., and I.I.P. contributed to the conception and design. P.K., S.A.M., K.C., D.M., E.P., G.H., R.D.M., and G.P.C. analyzed the experimental data. P.K., J.M.J., D.M., E.P., and I.I.P. collected muscle specimens. P.K., S.A.M., D.M., K.C., E.P., D.M.H., K.U., and I.I.P. collected and analyzed clinical data. G.H. and P.K. performed the statistical analysis. P.K., G.H., R.D.M., S.A.M., K.U., G.P.C., and I.I.P. drafted and made critical revisions to the article.

Disclosure: The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in the article.

Methods—Gastrocnemius biopsies were collected from 154 PAD patients (Fontaine stage II) and 85 control subjects. Morphometric parameters of gastrocnemius fibers were determined and evaluated for associations with walking distances and calf muscle strength.

Results—Compared with control myofibers, PAD myofiber cross-sectional area, major and minor axes, equivalent diameter, perimeter, solidity, and density were significantly decreased ($P < 0.005$), whereas roundness was significantly increased ($P < 0.005$). Myofiber morphometric parameters correlated with walking distances and calf muscle strength. Multiple regression analyses demonstrated myofiber cross-sectional area, roundness, and solidity as the best predictors of calf muscle strength and 6-min walking distance, whereas cross-sectional area was the main predictor of maximum walking distance.

Conclusions—Myofiber morphometrics of PAD gastrocnemius differ significantly from those of control muscle and predict calf muscle strength and walking distances of the PAD patients. Morphometric parameters of gastrocnemius myofibers may serve as objective criteria for diagnosis, staging, and treatment of PAD.

Keywords

Claudication; Walking distance; Myofiber morphology

1. Introduction

Peripheral artery disease (PAD) affects an estimated 27 million people in Europe and North America and is characterized by the formation of atherosclerotic plaques that limit blood flow to the legs [1,2]. The primary manifestation of PAD is claudication, a severe functional limitation identified as walking-induced pain or cramping in the muscles of the leg, relieved by rest [3]. More advanced disease is characterized by pain while at rest, classified as Fontaine stage III, and nonhealing foot ulcers and gangrene, classified as Fontaine stage IV [3].

Although the primary problem in PAD patients is the presence of atherosclerotic blockages in the arteries supplying their legs [4–7], altered, arterial hemodynamics is not the only cause of functional limitation in the lower limbs of PAD patients [8–14]. Several laboratories have demonstrated that a myopathy is present in the legs of patients with PAD and is a key component of the pathophysiology of PAD [4–6]. A number of studies based on light and electron microscopic evaluation of skeletal muscle from the legs of PAD patients have demonstrated that this myopathy is characterized by substantial abnormalities of the PAD muscle as illustrated in Figures 1 and 2. These abnormalities include myofiber degeneration with alteration of the size and shape of the myofibers, internal nuclei, target lesions, vacuolization, shift of myofiber phenotype toward type I fibers, myofiber necrosis, fatty infiltration, and endomysial and perimysial fibrosis [15–19]. Our group has quantified, precisely, parameters of myofiber morphology in PAD and control gastrocnemius samples obtained with minimally invasive needle biopsy. We found consistent and quantifiable changes in gastrocnemius myofiber morphology, which can separate PAD patients from controls and PAD patients with stage II disease from patients with critical limb ischemia [18,20]. In the present study, we evaluated myofiber morphometrics as predictors of

objective measures of the limb function (calf muscle strength and walking distances) of PAD patients. We hypothesized that in PAD patients, morphometric parameters of gastrocnemius myofibers correlate with calf muscle strength and walking distances.

2. Material and methods

2.1. Human subjects

The experimental protocol was approved by the Institutional Review Board, of the VA Nebraska-Western Iowa and the University of Nebraska Medical Centers, and all subjects gave informed consent. We recruited 154 patients evaluated for symptomatic PAD. For every patient, the diagnosis of PAD was established on the basis of medical history, physical examination, significantly decreased ankle-brachial index (ABI), and computerized or standard arteriography. We specifically excluded patients that had exercise capacity limited by conditions other than claudication including leg (joint/musculo-skeletal, neurologic) and systemic (heart, lung disease) pathology. We recruited 85 patients with normal blood flow to their lower limbs, undergoing lower extremity operations for indications other than PAD. These patients had no history of PAD symptoms, and all had normal lower extremity pulses at examination. All controls were selected to have normal ABIs at rest and after stress and all led sedentary lifestyles.

2.2. Muscle biopsy

Gastrocnemius samples were obtained from the anteromedial aspect of the muscle belly, 10-cm distal to the tibial tuberosity. All biopsies were obtained with a 6-mm Bergstrom needle. The samples were placed immediately into cold methacarn. After 48 h in methacarn, the specimens were transferred to cold ethanol:H₂O (50:50 v/v) and subsequently embedded in paraffin.

2.3. Histology

Masson trichrome staining was implemented with a kit from Thermo Fisher Scientific (#87019; Waltham, MA) according to the instructions provided with the kit. Briefly, paraffin-embedded biopsy specimens sectioned at 4 μ m were deparaffinized and fixed in Bouin solution overnight. After incubation in Weigert iron hematoxylin solution, the slides were stained with Biebrich scarlet-acid fuchsin and aniline blue and dehydrated in ethanol and xylene. Extensive washes were done between each staining. The collagen was stained blue, the nuclei were stained black, and the myofibers were stained red.

2.4. Fluorescence microscopy

Paraffin-embedded biopsies sectioned at 4 μ m were deparaffinized with xylene and rehydrated via a series of ethanol washes and distilled water. The rehydrated slide specimens were heated at 95° C in 100 mM citrate buffer (pH 6.0) for 15 min and then allowed to cool for 20 min. Subsequently, the slide specimens were soaked in Super-Sensitive Wash buffer (SS; BioGenex Laboratories, Fremont, CA) for 30 min at room temperature.

A programmable autostainer (BioGenex i6000; BioGenex Laboratories) was used to label sarcolemma and myosin heavy chains. For labeling of myofibers, specimens were blocked

with 10% goat serum and were treated with a mixture of mouse anti-type I myosin heavy chain (M8421, clone NOQ7.5.4D; Sigma–Aldrich, St. Louis, MO) and mouse anti-type II myosin heavy chain (M4276, clone MY-32; Sigma–Aldrich) antibodies, for 1 h. Subsequently, the slides were treated for 1 h with a mixture of goat anti-mouse IgG-Alexa Fluor 488 (A11029, Molecular Probes; Life Technologies, Grand Island, NY) and wheat germ agglutinin-Alexa Fluor 647, which label sarcolemma (W32466, Molecular Probes; Life Technologies). Finally, Pro-Long Gold antifade medium with the nuclear label 4',6-diamidino-2-phenylindole (P36931, Molecular Probes; Life Technologies) was applied to the labeled specimens.

2.5. Image acquisition and analysis

Gray-scale (12-bit) fluorescence images (1344×1044) were captured with a wide-field, epifluorescence microscope (Leica DMRXA2; North Central Instruments, Plymouth, MN) ($\times 10$ objective; $0.5128 \mu\text{m}/\text{pixel}$), a B/W CCD camera (Orca ER C4742-95; Hamamatsu Photonics, Bridgewater, NJ), and HCSImage Hamamatsu software (64-bit version 4.2.5; Hamamatsu Photonics). An acquisition matrix was programmed into the HCSImage software to cover the whole muscle specimen area, acquiring 100–150 microscopic frames per specimen yielding images of $134,400 \times 104,400$ to $201,600 \times 156,600$ pixels. At each location, images were collected in fluorescence channels corresponding to each fluorophore; 1) 4',6-diamidino-2-phenylindole (nuclei) with an excitation maximum at 358 nm and emission maximum at 461 nm, 2) Alexa Fluor 488 (myosin heavy chains) with an excitation maximum at 495 nm and emission maximum at 519 nm, and 3) Alexa Fluor 647 (sarcolemma) with an excitation maximum 650 nm and emission maximum at 668 nm. The frames corresponding to each fluorophore were montaged in one large image to represent the given (whole) specimen. Image segmentation was done with a custom-made Matlab algorithm (R2012a; MathWorks Inc, Natick, MA), using thresholding, edge detection, regionprops, and a set of heuristics [18,20]. Labeled sarcolemma acquired at 668 nm provided a binary image that served as an outline for each myofiber. The sarcolemma outline was then superimposed on the image of myosin heavy chains, allowing precise identification of the myofibers for analysis. For each specimen, we extracted measurements of myofiber size, shape, and density. The methods describing how these parameters were measured have been described in detail [18,20]. Briefly, we calculated the following parameters of myofiber size: 1) myofiber cross-sectional area (μ^2), from the number of pixels enclosed within a segmented myofiber, 2) major and minor axes (μ), of an ellipse fitted in the myofiber, 3) equivalent diameter (μ), as the diameter of a circle that has the same area as the segmented myofiber, and 4) myofiber perimeter (μ), from the number of pixels on the boundary of the myofiber. We calculated the following parameters of myofiber shape: 1) roundness, as the equivalent diameter $\times \pi$ divided by the perimeter of the segmented myofiber, and 2) solidity, defined as the myofiber cross-sectional area divided by the area of a fitted convex hull. A fitted convex hull is the smallest convex polygon that can encompass the myofiber. Finally, myofiber density was measured as the area occupied by the myofibers divided by the area occupied by the myofibers plus interstitial tissue. In terms of biological relevance, we expect that these mathematical equations will provide objective measures that quantitatively reflect pathologic changes in the muscle, including myofiber degeneration, necrosis, or apoptosis (myofiber cross-sectional area, perimeter, equivalent

diameter, roundness, and solidity), loss of the normal polygonal myofiber shape (myofiber roundness and solidity), and replacement of muscle by fibrous and/or adipose tissues (myofiber density).

2.6. Muscle strength measurement

Muscle force production from the ankle plantar flexors was measured using a Biodex dynamometer (System 4.0; Biodex Medical Systems, Shirley, NY). The PAD patients were secured onto the Biodex and the standard ankle plantar flexion/dorsi-flexion position of 90° angle between the foot and the shank was used. To isolate the plantar flexor muscles, the ipsilateral thigh, waist, and chest of the patients were secured. The parameter of the muscle strength we measured was the peak force produced by the ankle plantar flexors (the muscles of the posterior compartments of the calf) during a maximum isometric contraction of 10-s duration. Data are represented in $\text{ft} \times \text{lbs}$.

2.7. Graded treadmill test and 6-min walking distance

Maximum walking distance was measured for all PAD patients using the Gardner graded treadmill test. The patients walked at a constant speed of $3.2 \text{ km} \cdot \text{h}^{-1}$ on a 0° grade, followed by 2° grade increase every 2 min. All PAD patients were also evaluated with the 6-min walk test. The test was performed in an indoor 20-m hallway for 6 min. The procedure was performed under technical supervision, and the patient was given instructions to cover as much distance as possible.

2.8. Statistical analyses

Baseline characteristics between PAD patients and control subjects were compared using chi-square or Fisher exact tests for categorical variables and independent *t*-tests for continuous variables. A one-way analysis of covariance was used to identify differences between PAD and control groups for all the morphometric parameters adjusting for any significant covariates. Bivariate correlations were used to correlate morphometric parameters with limb function and muscle strength parameters. The data were standardized, and multiple regression analyses with stepwise regression were used to identify predictors of calf muscle strength and walking distances. All analyses were performed using SAS statistical software version 9.3 (SAS Institute Inc, Cary, NC). All the data are presented as mean $\pm$ standard error of the mean.

3. Results

3.1. Subject demographics

The demographic information for both the PAD and control subjects is presented in Table 1. Gender ($\chi^2 = 18.8$, $P < 0.001$), smoking status ($\chi^2 = 25.3$, $P < 0.001$), coronary artery disease ($\chi^2 = 5.4$, $P = 0.022$), family history of PAD ($\chi^2 = 4.6$, $P = 0.036$), dyslipidemia ($\chi^2 = 5.3$, $P = 0.029$) and ABI ($t = -20.3$, $P < 0.001$) were significantly different between the PAD and control subjects. Subsequently, these parameters were used as covariates in the rest of the analyses to control their effects on the myopathy of PAD.

3.2. Gastrocnemius specimens of PAD patients exhibited abnormal myofiber morphology and density compared with controls

In PAD gastrocnemius, myofiber cross-sectional area, major axis, minor axis, equivalent diameter, and perimeter, were significantly reduced compared with those of controls. Moreover, PAD myofibers exhibited abnormal shape having increased roundness and decreased solidity. Finally, we observed a decrease in myofiber density per unit area of cross-sectioned specimen (Table 2).

3.3. Calf muscle strength and walking distances of PAD patients change with myofiber morphology and density

The observed differences between PAD and control gastrocnemius myofibers suggested that myofiber morphometrics may correlate with calf muscle strength and walking distances (Table 3). Calf muscle strength increased with increasing myofiber cross-sectional area, major axis, minor axis, equivalent diameter, perimeter, solidity, and fiber density. In contrast, calf muscle strength decreased with increasing myofiber roundness, a measure of abnormal myofiber morphology. Similarly, 6-min walking distance increased with increasing myofiber cross-sectional area, major axis, equivalent diameter, perimeter, solidity, and fiber density and decreased with increasing myofiber roundness. Finally, maximum walking distance increased with increasing myofiber cross-sectional area, major axis, minor axis, and equivalent diameter and perimeter increased with increasing maximum walking distance and decreased with increasing myofiber roundness. Based on these observations, we performed multiple regression analyses with stepwise regression to identify the best morphometric predictors of calf muscle strength and walking distances. Calf muscle strength was predicted by myofiber cross-sectional area, roundness, and solidity ($r^2 = 0.617$, $r = 0.786$, $P < 0.001$) according to the following equation:

$$\text{Calf Muscle Strength(ft*lbs)} = -123 + 0.450 * \text{Area} - 0.333 * \text{Roundness} + 0.260 * \text{Solidity}$$

Plots of calf muscle strength versus myofiber cross-sectional area, roundness, and solidity are presented in Figure 3. Six-minute walking distance was predicted by myofiber cross-sectional area, roundness, and solidity ($r^2 = 0.321$, $r = 0.566$, $P < 0.001$) according to the following equation:

$$\text{Six Minute Walking Distance(m)} = -586 + 0.388 * \text{Area} - 0.180 * \text{Roundness} + 0.179 * \text{Solidity}$$

Maximum walking distance was predicted only by myofiber cross-sectional area ($r^2 = 0.295$, $r = 0.543$, $P < 0.001$) according to the following equation:

$$\text{Maximum Walking Distance(m)} = -107 + 0.543 * \text{Area}$$

4. Discussion

Our study shows that precise morphometric analysis of needle biopsy specimens identifies specific and consistent aberrations in the gastrocnemius myofibers of patients with PAD. More importantly, our data show, for the first time, that these objectively defined parameters of gastrocnemius myofiber morphology are closely linked to the calf muscle strength and walking distances of claudicating PAD patients. Using fluorescence microscopy and detailed image processing, we demonstrated that multiple parameters of myofiber size (cross-sectional area, major and minor axes, equivalent diameter, and perimeter), shape (roundness and solidity), and density are significantly altered in the PAD gastrocnemius compared with those of control. Furthermore, using statistical modeling, we found that the changes in the cross-sectional area, roundness, and solidity of the gastrocnemius myofibers are strong predictors of muscle strength and 6-min and maximum walking distances of the claudicating patients.

Our report represents, thus far, the largest quantitative study of the histopathology of the affected skeletal muscle of claudicating patients. A widely held view concerning the pathophysiology of claudication has been that limb dysfunction and walking limitation of claudicating patients are produced exclusively by exercise-induced ischemia in the muscles of the lower limb. Published work from our group and others [4–6,21] has revised this view by documenting the presence of a myopathy in leg muscles of patients with PAD and demonstrating a constellation of baseline, gait abnormalities of rested patients, before the onset of claudication [10,11,22–25], when tissue oxygen levels [26] and blood flow [13] in the leg are similar to (and sometimes even higher than) those of controls. Furthermore, measurements of muscle strength in PAD patients determined as 5-s maximal isometric strength, a blood flow-independent assessment [12], demonstrated that muscle strength in PAD patients is significantly reduced compared with that of controls. The present work lends particular support to the importance of myopathy to the functional impairment of patients with claudication by establishing the presence of a strong correlation between myofiber morphometrics and both calf muscle strength and walking distances. Our data demonstrate that myofiber morphometric parameters (including combinations of cross-sectional area, major axis, minor axis, equivalent diameter, perimeter, roundness, solidity, and density) were stronger correlates of calf muscle strength, 6-min walking distance and treadmill maximum walking distance than ABI, which represents the degree of arterial obstruction.

The myopathy of claudicating muscle is readily observed in histologic preparations of gastrocnemius specimens from PAD patients (Figs. 1 and 2). PAD muscle displays different patterns of myofiber degeneration with alteration of the size and shape of the myofibers [2,15,18,19], internal nuclei, target lesions, vacuolization, shift of myofiber phenotype toward type I fibers, myofiber necrosis, fatty infiltration and endomysial, perimysial and epimysial fibrosis [15–19]. In addition, the myopathy of PAD muscle has been observed by computerized tomographic scanning of the calf muscles of claudicating patients, demonstrating smaller muscle volume, higher fat content, and lower muscle density [27]. More detailed evaluation of the ultrastructure, physiology, and biochemistry of claudicating muscle reveals that the primary pathophysiological features of this myopathy are

mitochondrial dysfunction, oxidative damage, and inflammation [2,6,27–30]. The widely held view is that PAD myopathy is caused by repetitive cycles of ischemia–reperfusion [4–6], which initiate mitochondrial dysfunction and injury and produce inflammation and oxidative damage. In the long term, repeated oxidative and inflammatory insults to the myofiber [31–33] are expected to produce myofiber degeneration and the associated changes in the myofiber morphometry we have established with our present work.

This is a correlational study demonstrating that the myofiber size and shape are abnormal in PAD gastrocnemius and that these changes correlate with limb dysfunction (impaired calf muscle strength and walking distances) in PAD patients. The study does not identify cause/effect relationships; however, the high quality human data we have produced demonstrate that grading of myofiber degeneration can serve as a measure of the progression of damage and dysfunction in PAD limbs and may allow objective determination, at the tissue level, of the outcomes produced by pharmacologic and surgical therapies in patients with PAD.

The association between myofiber characteristics and limb function has been observed in a small number of studies of patients with pathologic states that affect the skeletal muscles of the lower extremities and healthy volunteers. In a study of 10 patients with unilateral PAD [19], gastrocnemius muscle strength of the symptomatic leg correlated with total calf cross-sectional area and cross-sectional area occupied by type II myofibers. The study did not have enough power to explore correlations with maximum walking time or area occupied by type I myofibers. In a slightly larger study of 25 males with limb-girdle muscular dystrophy 2A [34], myofiber size correlated with the clinical disability score of the patients [34]. Expression of muscle-specific RING finger protein 1, a ubiquitin-protein ligase closely associated with myofiber proteolysis, was increased in limb-girdle muscular dystrophy 2A muscle and correlated with reduced myofiber cross-sectional area and decreased muscle performance. Finally, in a study of the quadriceps muscle of 48 college students [35], immobilization reduced myosin heavy chain transcripts in association with reduced myofiber cross-sectional area and reduced muscle strength. After retraining, muscle fiber cross-sectional increased in association with increased muscle strength. It will be of interest to evaluate the effects of interventions including exercise therapy, nutritional therapy, and pharmacotherapy with medications that enhance mitochondrial function and antioxidant defenses, androgens, growth hormone, ghrelin, myostatin inhibitors, and anti-inflammatory agents [36–40] on myofiber morphometrics in relation to muscle strength and leg function of patients with PAD.

5. Conclusions

In summary, morphologic damage to myofibers can be precisely quantified using gastrocnemius specimens obtained with minimally invasive needle biopsy. Statistical modeling based on myofiber morphometrics established a correlation between advancing myofiber degeneration and functional decline in PAD patients. Our work has established a comprehensive profile of quantitative morphometric changes in PAD muscle, which can serve as a guide for more extensive mechanisms and intervention studies essential for much needed improvement of diagnosis, staging, and treatment of PAD.

Acknowledgments

This work was primarily supported by NIH grant R01AG034995, by the Charles and Mary Heider Fund for Excellence in Vascular Surgery, by the Alexander S. Onassis Public Benefit Foundation F-ZD036, and by the American Heart Association Pre-Doctoral Fellowship 13PRE13860010. Secondary funding was provided by the Department of Veterans' Affairs, Veterans Health Administration, Rehabilitation Research, and Development Service 1101RX000604 and by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number P20GM109090. The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Furthermore, this material is the result of work supported with resources and the use of facilities at the VA Nebraska-Western Iowa Health Care System.

References

1. Roger VL, Go AS, Lloyd-Jones DM, et al. American Heart Association Statistics C. Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics—2012 update: a report from the American Heart Association. *Circulation*. 2012; 125:188. [PubMed: 22215894]
2. Weiss DJ, Casale GP, Koutakis P, et al. Oxidative damage and myofiber degeneration in the gastrocnemius of patients with peripheral arterial disease. *J Translational Med*. 2013; 11:230.
3. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). *J Vasc Surg*. 2007; 45(Suppl S):S5. [PubMed: 17223489]
4. Brass EP, Hiatt WR. Acquired skeletal muscle metabolic myopathy in atherosclerotic peripheral arterial disease. *Vasc Med*. 2000; 5:55. [PubMed: 10737157]
5. Pipinos II, Judge AR, Selsby JT, et al. The myopathy of peripheral arterial occlusive disease: part 1. Functional and histomorphological changes and evidence for mitochondrial dysfunction. *Vasc Endovascular Surg*. 2007; 41:481. [PubMed: 18166628]
6. Pipinos II, Judge AR, Selsby JT, et al. The myopathy of peripheral arterial occlusive disease: part 2. Oxidative stress, neuropathy, and shift in muscle fiber type. *Vasc Endovascular Surg*. 2008; 42:101. [PubMed: 18390972]
7. McDermott MM, Liu K, Tian L, et al. Calf muscle characteristics, strength measures, and mortality in peripheral arterial disease: a longitudinal study. *J Am Coll Cardiol*. 2012; 59:1159. [PubMed: 22440216]
8. Gardner AW, Killewich LA. Lack of functional benefits following infrainguinal bypass in peripheral arterial occlusive disease patients. *Vasc Med*. 2001; 6:9. [PubMed: 11358164]
9. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Prediction of claudication pain from clinical measurements obtained at rest. *Med Sci Sports Exerc*. 1992; 24:163. [PubMed: 1549004]
10. Koutakis P, Johanning JM, Haynatzki GR, et al. Abnormal joint powers before and after the onset of claudication symptoms. *J Vasc Surg*. 2010; 52:340. [PubMed: 20670775]
11. Koutakis P, Pipinos II, Myers SA, Stergiou N, Lynch TG, Johanning JM. Joint torques and powers are reduced during ambulation for both limbs in patients with unilateral claudication. *J Vasc Surg*. 2010; 51:80. [PubMed: 19837536]
12. McDermott MM, Criqui MH, Greenland P, et al. Leg strength in peripheral arterial disease: associations with disease severity and lower-extremity performance. *J Vasc Surg*. 2004; 39:523. [PubMed: 14981443]
13. Pernow B, Zetterquist S. Metabolic evaluation of the leg blood flow in claudicating patients with arterial obstructions at different levels. *Scand J Clin Lab Invest*. 1968; 21:277. [PubMed: 5708696]
14. Pipinos II, Judge AR, Zhu Z, et al. Mitochondrial defects and oxidative damage in patients with peripheral arterial disease. *Free Radic Biol Med*. 2006; 41:262. [PubMed: 16814106]
15. Hedberg B, Angquist KA, Henriksson-Larsen K, Sjostrom M. Fibre loss and distribution in skeletal muscle from patients with severe peripheral arterial insufficiency. *Eur J Vasc Surg*. 1989; 3:315. [PubMed: 2767254]
16. Hedberg B, Angquist KA, Sjostrom M. Peripheral arterial insufficiency and the fine structure of the gastrocnemius muscle. *Int Angiol*. 1988; 7:50. [PubMed: 3385269]
17. Makitie J, Teravainen H. Histochemical changes in striated muscle in patients with intermittent claudication. *Arch Pathol Lab Med*. 1977; 101:658. [PubMed: 579309]

18. Koutakis P, Weiss DJ, Miserlis D, et al. Oxidative damage in the gastrocnemius of patients with peripheral artery disease is myofiber type selective. *Redox Biol.* 2014; 2:921. [PubMed: 25180168]
19. Regensteiner JG, Wolfel EE, Brass EP, et al. Chronic changes in skeletal muscle histology and function in peripheral arterial disease. *Circulation.* 1993; 87:413. [PubMed: 8425290]
20. Cluff K, Miserlis D, Naganathan GK, et al. Morphometric analysis of gastrocnemius muscle biopsies from patients with peripheral arterial disease: objective grading of muscle degeneration. *Am J Physiol Regul Integr Comp Physiol.* 2013; 305:R291. [PubMed: 23720135]
21. Koutakis P, Miserlis D, Myers SA, et al. Abnormal accumulation of desmin in gastrocnemius myofibers of patients with peripheral artery disease: associations with altered myofiber morphology and density, mitochondrial dysfunction and impaired limb function. *J Histochem Cytochem.* 2015 Epub ahead of print.
22. Celis R, Pipinos II, Scott-Pandorf MM, Myers SA, Stergiou N, Johanning JM. Peripheral arterial disease affects kinematics during walking. *J Vasc Surg.* 2009; 49:127. [PubMed: 19028062]
23. Myers SA, Pipinos II, Johanning JM, Stergiou N. Gait variability of patients with intermittent claudication is similar before and after the onset of claudication pain. *Clin Biomech.* 2011; 26:729.
24. Scott-Pandorf MM, Stergiou N, Johanning JM, Robinson L, Lynch TG, Pipinos II. Peripheral arterial disease affects ground reaction forces during walking. *J Vasc Surg.* 2007; 46:491. [PubMed: 17826236]
25. Wurdeman SR, Koutakis P, Myers SA, Johanning JM, Pipinos II, Stergiou N. Patients with peripheral arterial disease exhibit reduced joint powers compared to velocity-matched controls. *Gait & Posture.* 2012; 36:506. [PubMed: 22677467]
26. Bauer TA, Brass EP, Hiatt WR. Impaired muscle oxygen use at onset of exercise in peripheral arterial disease. *J Vasc Surg.* 2004; 40:488. [PubMed: 15337878]
27. McDermott MM, Guralnik JM, Ferrucci L, et al. Physical activity, walking exercise, and calf skeletal muscle characteristics in patients with peripheral arterial disease. *J Vasc Surg.* 2007; 46:87. [PubMed: 17540532]
28. Makris KI, Nella AA, Zhu Z, et al. Mitochondriopathy of peripheral arterial disease. *Vascular.* 2007; 15:336. [PubMed: 18053417]
29. Brevetti G, Giugliano G, Brevetti L, Hiatt WR. Inflammation in peripheral artery disease. *Circulation.* 2010; 122:1862. [PubMed: 21041698]
30. Spirig R, Tsui J, Shaw S. The emerging role of TLR and innate immunity in cardiovascular disease. *Cardiol Res Pract.* 2012; 2012:181394. [PubMed: 22577589]
31. Bloch RJ, Gonzalez-Serratos H. Lateral force transmission across costameres in skeletal muscle. *Exerc Sport Sci Rev.* 2003; 31:73. [PubMed: 12715970]
32. Sanger, JW.; Sanger, JM.; Franzini-Armstrong, C. Assembly of the skeletal muscle cell. In: Engel, AG.; Franzini-Armstrong, C., editors. *Myology*. New York, NY, USA: McGraw-Hill; 2004. p. 45
33. Sanger JW, Wang J, Fan Y, White J, Sanger JM. Assembly and dynamics of myofibrils. *J Biomed Biotechnol.* 2010; 2010:858606. [PubMed: 20625425]
34. Fanin M, Nascimbeni AC, Angelini C. Muscle atrophy in limb girdle muscular dystrophy 2A: a morphometric and molecular study. *Neuropathol Appl Neurobiol.* 2013; 39:762. [PubMed: 23414389]
35. Hortobagyi T, Dempsey L, Fraser D, et al. Changes in muscle strength, muscle fibre size and myofibrillar gene expression after immobilization and retraining in humans. *J Physiol.* 2000; 524(Pt 1):293. [PubMed: 10747199]
36. Dodson S, Baracos VE, Jatoi A, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. *Annu Rev Med.* 2011; 62:265. [PubMed: 20731602]
37. Creasy TS, McMillan PJ, Fletcher EW, Collin J, Morris PJ. Is percutaneous transluminal angioplasty better than exercise for claudication? Preliminary results from a prospective randomised trial. *Eur J Vasc Surg.* 1990; 4:135. [PubMed: 2140987]
38. Brotto M, Abreu EL. Sarcopenia: pharmacology of today and tomorrow. *J Pharmacol Exp Ther.* 2012; 343:540. [PubMed: 22929991]
39. Barillaro C, Liperoti R, Martone AM, Onder G, Landi F. The new metabolic treatments for sarcopenia. *Aging Clin Exp Res.* 2013; 25:119. [PubMed: 23739896]

40. Chumlea WC, Cesari M, Evans WJ, et al. International Working Group on Sarcopenia Task Force Members. Sarcopenia: designing phase IIB trials. *J Nutr Health Aging*. 2011; 15:450. [PubMed: 21623466]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Fig. 1. Normal histology of the gastrocnemius of a control patient. The muscle biopsy was fixed in methacarn, embedded in paraffin, and sectioned at 4 μm . Slide-mounted sections were stained with Masson trichrome and captured with a $\times 10$ objective (panel A). Regions identified with black frames were captured with a $\times 40$ objective and are presented as separate panels (B and C). The myofibers (red), exhibiting a regular polygonal shape, little size variation, and peripherally located nuclei (black), were tightly packed within a thin investment of connective tissue (blue). The white bars represent 100 μm (panel A) and 50 μm (panels B and C). (Color version of figure is available online.)

Fig. 2.

Severe myopathy in the gastrocnemius of a patient with PAD. The muscle biopsy was fixed in methacarn, embedded in paraffin, and sectioned at 4 μm . Slide-mounted sections were stained with Masson trichrome and captured with a $\times 10$ objective (panel A). The myofibers (red), exhibiting a nonpolygonal round shape, large variation in size and nuclei (black) often present in the interior, were embedded in an abundant collagenous matrix (blue). Regions identified with black frames were captured with a $\times 40$ objective and are presented as separate panels (B–G; next page). Degradation and loss of myofibers, clearly apparent in panels (B–G), are associated with a remarkable increase of collagen deposition (arrow heads) in the extracellular matrix and the appearance of myofiber vacuoles (filled arrows), target lesions (chevrons), and more centrally located nuclei (unfilled arrows). The white bars represent 100 μm (panel A) and 50 μm (Panels B–G). (Color version of figure is available online.)

Fig. 3.

Scatterplots showing correlations between calf muscle strength and myofiber cross-sectional area (μ^2), roundness, and solidity in claudicating patients ($n = 154$). Calf muscle strength increased with increasing myofiber cross-sectional area and solidity and decreased with increasing myofiber roundness.

Table 1
Baseline characteristics of control and PAD patients

Baseline characteristics	Control	PAD	P value
Number of subjects	85	154	N/A
Mean age (y)	62.5 ± 9.8	62.9 ± 7.5	0.738
Height (m)	1.76 ± 0.08	1.76 ± 0.07	0.959
Weight (kg)	91.2 ± 16.9	86.67 ± 18.4	0.066
ABI	1.08 ± 0.08	0.51 ± 0.25	<0.001
RACE % (W/AA/H/IND)	95.2/2.4/2.4/0	91.6/7.1/0.65/0.65	0.240
Gender % (male/female)	81.2/18.8	97.4/2.6	<0.001
Smoking status % (never/current/former)	42.4/30.5/27.1	3.9/60.4/35.7	<0.001
Coronary artery disease, %	23.50	38.30	0.022
Family history of PAD, %	20.00	33.10	0.036
Obesity, %	31.80	25.30	0.294
Diabetes, %	23.50	31.80	0.184
Dyslipidemia, %	58.80	73.40	0.029
Hypertension, %	67.10	77.90	0.089

N/A = not applicable.

Race, (W) White, (AA) African American, (H) Hispanic, (IND) American Indian.

Table 2
Myofiber morphometrics of the gastrocnemius of control and PAD patients

Myofiber morphometrics	Control	PAD	<i>P</i> value
Cross-sectional area (μ^2)	5047 $\pm$ 139	4215 $\pm$ 100	<0.001
Major axis (μ)	104.48 $\pm$ 2.1	96.53 $\pm$ 1.5	0.003
Minor axis (μ)	60.06 $\pm$ 1.7	53.51 $\pm$ 1.3	0.003
Equivalent diameter (μ)	76.21 $\pm$ 1.2	70.64 $\pm$ 0.8	<0.001
Perimeter (μ)	303.79 $\pm$ 5.6	280.57 $\pm$ 4.1	0.001
Roundness	0.799 $\pm$ 0.004	0.814 $\pm$ 0.003	0.005
Solidity	0.947 $\pm$ 0.002	0.938 $\pm$ 0.001	<0.001
Myofiber density	0.823 $\pm$ 0.007	0.772 $\pm$ 0.005	<0.001

P values were adjusted for ABI, dyslipidemia, coronary artery disease, gender, and family history of PAD.

Table 3
Correlations of myofiber morphometrics in the PAD gastrocnemius with calf muscle strength and walking distances

Myofiber morphometrics	Calf muscle strength (ft × lbs)	6 min walking distance (m)	Maximum walking distance (m)
ABI	0.401 [†]	0.217 [*]	0.211 [*]
Cross-sectional area (μ ²)	0.615 [†]	0.443 [†]	0.483 [†]
Major axis (μ)	0.608 [†]	0.360 [†]	0.390 [†]
Minor axis (μ)	0.419 [†]	0.103	0.201 [*]
Equivalent diameter (μ)	0.587 [†]	0.391 [†]	0.408 [†]
Perimeter (μ)	0.60 [†]	0.382 [†]	0.342 [†]
Roundness	-0.430 [†]	-0.285 [*]	-0.204 [*]
Solidity	0.486 [†]	0.251 [*]	0.105
Myofiber density	0.219 [*]	0.221 [*]	0.125

^{*} $P < 0.05$.

[†] $P < 0.001$.